Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alnuctamab plus mezigdomide in relapsed or refractory multiple myeloma
MOH_2023-08-15_012883Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Nov 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of alnuctamab and mezigdomide in multiple myeloma (MM) (3 arms), sponsored by Celgene Corporation. Primary endpoints: Safety and Recommended dose and schedule determination. Started Nov 2023; status: completed.
02
Drugs
alnuctamabmezigdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2023-08-15_012883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-08-15_012883.